Skip to content
DataLookout
Menu

NCT05256290

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 3 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 30 versions: 29 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Nov 3, 2025 to Mar 2028 Show 9 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment reopened
    • Eligibility criteria expanded, about 29 words
    • Enrollment increased: 200 → 220 participants
    • Trial sites reduced: 25 → 19 locations
    • Study completion pushed from Dec 2027 to Jun 2028
    • Interventions modified
    • Trial arms changed: 4 → 5
    • Secondary endpoints: 8 to 3
  2. Minor Study completion date: Jun 2026 to Dec 2027v29
  3. Minor Study sites: 41 to 25
    • Primary completion date changed from estimate of Jul 2025 to Nov 3, 2025
    v28
  4. Notable Primary endpoints revised (2)v27 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Interventions: BDTX-1535 monotherapy (Drug) to silevertinib (BDTX-1535) monotherapy (Drug)
    • Secondary endpoints: 11 to 8
    • Site details revised at 41 of 41 sites
    • Study title expanded, about 1 word
  5. Minor Study sites: 42 to 41v26
Show 23 earlier versionsHide 23 earlier versions
  1. Minor Study sites: 38 to 42v25
  2. Minor Study sites: 37 to 38v24
  3. Minor Study sites: 31 to 37v23
  4. Minor Site contacts updated at 8 of 31 sitesv22
  5. Minor Study sites: 24 to 31v21
  6. Notable Primary completion date: Jun 2024 to Jul 2025
    • Eligibility criteria expanded, about 55 words
    • Study sites: 26 to 24
    • Study completion date: Mar 2025 to Jun 2026
    v20
  7. Minor Study sites: 24 to 26v19
  8. Notable Eligibility criteria shortened, about 3 wordsv18
  9. Minor Study sites: 20 to 24v17
  10. Notable Phase: Phase 1 to Phase 1/2v16 Show 8 more changesShow less
    • Enrollment target: 120 to 200
    • Eligibility criteria shortened, about 77 words
    • Primary endpoints revised (2)
    • Study sites: 19 to 20
    • Interventions: BDTX-1535 in combination with temozolomide (Drug), BDTX-1535 monotherapy (Drug) to BDTX-1535 monotherapy (Drug)
    • Secondary endpoints: 18 to 11
    • Study arms: 3 to 4
    • Study title expanded, about 2 words
  11. Minor Study sites: 17 to 19v14
  12. Minor Study sites: 15 to 17v13
  13. Notable Primary completion date: Apr 2023 to Jun 2024v12 Show 9 more changesShow less
    • Eligibility criteria shortened, about 81 words
    • Primary endpoints: 1 to 2
    • Enrollment target: 90 to 120
    • Study completion date: Sep 2024 to Mar 2025
    • Interventions: BDTX-1535 Monotherapy (Drug), BDTX-1535 Monotherapy Dose Escalation (Drug) to BDTX-1535 in combination with temozolomide (Drug), BDTX-1535 monotherapy (Drug)
    • Secondary endpoints: 8 to 18
    • Study description shortened, about 105 words
    • Study arms: 2 to 3
    • Study title expanded, about 3 words
  14. Minor Study sites: 11 to 15v11
  15. Minor Study sites: 10 to 11v10
  16. Minor Study sites: 8 to 10v9
  17. Minor Study sites: 7 to 8v8
  18. Minor Study sites: 6 to 7v7
  19. Minor Study sites: 5 to 6v6
  20. Minor Study sites: 4 to 5v5
  21. Minor Study sites: 3 to 4
    • Start date changed from estimate of Mar 2022 to Mar 31, 2022
    v4
  22. Minor Study sites: 2 to 3v3
  23. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1 Dose Escalation: To determine the maximum tolerated dose (MTD), if one exists, and the preliminary recommended Phase 2 dose(s) (RP2D[s]) of silevertinib (BDTX-1535)
Timeframe: The first treatment 21-day cycle (Cycle 1)
Phase 2 (Cohorts 1, 2, and 3): To assess antitumor efficacy of silevertinib (BDTX-1535)
Timeframe: Day 1 every 2 cycles starting on Cycle 3 Day 1 to study completion, approximately 1 year (each cycle is 21 days)
Phase 2 Cohort 4 Only: To assess the safety and tolerability of silevertinib at the 150 mg QD dose
Timeframe: Through study completion, approximately 1 year

Secondary (3)

Phase 1: To assess the preliminary antitumor activity of silevertinib (BDTX-1535) by objective response as assessed by RECIST version 1.1 (for patients with NSCLC) or Response Assessment in Neuro-oncology (RANO) (for patients with GBM)
Phase 2: To assess progression free survival by RECIST version 1.1
Phase 2 Cohort 4 Only: To assess antitumor efficacy of silevertinib (BDTX-1535)

Arms and interventions

Phase 1 Dose Escalation - Monotherapy (Recruitment Closed)Experimental

* Advanced/metastatic NSCLC with acquired resistance EGFR mutation (eg, C797S), following a 3rd generation EGFR inhibitor in the 1st line setting (in the absence of concurrent T790M). * Advanced/metastatic NSCLC with non-classical EGFR mutation (eg, G719X) following standard-of-care therapy with an EGFR inhibitor * Recurrent GBM with confirmed EGFR alterations (including amplification, mutation, and/or variant)

Phase 2 Cohort 1: NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)Experimental

Advanced/metastatic NSCLC with a non-classical driver EGFR mutation following up to 2 lines of therapy with only 1 prior EGFR targeted regimen (third-generation preferred; other approved EGFR inhibitors acceptable)

Phase 2 Cohort 2: NSCLC EGFR Acquired Resistance (C797S) Mutation (Recruitment Closed)Experimental

Advanced/metastatic NSCLC with the acquired resistance C797S EGFR mutation following up to 2 lines of therapy, including only 1 EGFR targeted regimen, which must be a third generation EGFR TKI (eg, osimertinib)

Phase 2 Cohort 3: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations (Recruitment Closed)Experimental

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 3 is 200 mg QD.

Phase 2 Cohort 4: Treatment Naive NSCLC EGFR Non-Classical Driver Mutations at 150 mg QD DoseExperimental

Treatment-naïve (first-line) advanced/metastatic NSCLC with a non-classical driver EGFR mutation (1 cycle of chemotherapy or immune checkpoint inhibitor are permitted). Patients with co-occurring L858R mutations and a non-classical mutation are eligible for inclusion. Silevertinib dose for Cohort 4 is 150 mg QD.

Drugs: silevertinib monotherapy

Sites

19 sites in 2 countries

United States 17, Canada 2